Advertisement
Piper Jaffray 7th Annual China Growth Conference on Thursday, May 13, 2010in New York City. Management is scheduled to present at 9:30 am ET on Thursday,May 13, and will be available to meet with institutional investors throughoutthe conference.
Advertisement
Rodman & Renshaw Annual Global Investment Conference on May 16-18, 2010 atthe Grosvenor House Hotel in London, UK. Management is scheduled to present at10:40 am BST on Monday, May 17, and will be available to meet withinstitutional investors throughout the conference.
Brean Murray, Carret & Co. 2010 Life Sciences Summit on Monday, May 17,2010 at The Grand Hyatt Hotel in New York City. Management is scheduled toparticipate in the Winners and Losers of China Healthcare Reform panel at 2:00pm ET and will be available to meet with institutional investors throughoutthe conference.
Oppenheimer & Co.'s 4th Annual China Dragon Call Conference on May 18-20,2010 in New York City. Management is scheduled to present at 1:10 pm ET onTuesday, May 18, and will be available to meet with institutional investorsthroughout the conference.
For further details, please contact your respective institutional salesrepresentative.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceuticalcompany that develops, manufactures and markets a diversified portfolio ofproducts focused on conditions with a high incidence and high mortality ratesin China, including cardiovascular, CNS, infectious, and digestive diseases.The Company's cost-effective, high margin business model is driven by marketdemand and supported by eight scalable GMP-certified product lines coveringthe major dosage forms. In addition, the Company has a broad and expandingnationwide distribution network across 30 provinces, municipalities andautonomous regions. The Company's wholly owned subsidiary, Hainan HelpsonMedical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province.For more information about China Pharma Holdings, Inc., please visithttp://www.chinapharmaholdings.com .
Safe Harbor Statement under the Private Securities Litigation Reform Actof 1995
Certain statements in this press release constitute forward-lookingstatements for purposes of the safe harbor provisions under The PrivateSecurities Litigation Reform Act of 1995. Any statements set forth above thatare not historical facts are forward-looking statements that involve risks anduncertainties that could cause actual results to differ materially from thosein the forward-looking statements, which may include, but are not limited to,such factors as success of new product development, unanticipated changes inproduct demand, increased competition, downturns in the Chinese economy,uncompetitive levels of research and development, and other informationdetailed from time to time in the Company's filings and future filings withthe United States Securities and Exchange Commission. The forward-lookingstatements made herein speak only as of the date of this press release and theCompany undertakes no duty to update any forward-looking statement to conformthe statement to actual results or changes in the company's expectations.For more information, please contact: China Pharma Holdings, Inc. Phone: +86-898-6681-1730 (China) Email: [email protected] CCG Investor Relations Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: [email protected] Vivian Chen, Sr. Market Intelligence Exec. Phone: +1-646-701-7445(New York) Email: [email protected]
SOURCE China Pharma Holdings, Inc.
